Enhancement of sensitivity of human lung cancer cell line to TRAIL and gefitinib by IGF-1R blockade

Yoon Jin Lee, Mi Young Park, youngae kang, Sung Youn Kwon, Ho Il Yoon, Jae Ho Lee, Choon Taek Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: TRAIL is a cytokine that selectively induces apoptosis in various cancer cell lines. Gefitinib is new targeted drug applied in lung cancer that selectively inhibits EGFR tyrosine kinase. However, lung cancers have shown an initial or acquired resistance to these drugs. This study examined the effect of IGF-1R and its blockade on enhancing the sensitivity of lung cancer cell lines to TRAIL and gefitinib. Methods: Two lung cancer cell lines were used in this study. NCI H460 is very sensitive to TRAIL and gefitinib. On the other hand, A549 shows moderate resistance to TRAIL and gefitinib. The IGF-1R blockade was performed using adenoviruses expressing the dominant negative IGF-1R and shRNA to IGF-1R and AG1024 (IGF-1R tyrosine kinase inhibitor). Results: The adenovirus expressing dominant negative IGF-1R(950st) induced the increased expression of defective IGF-1R on the lung cancer cell surface, and the adenovirus-shIGF-1R effectively decreased the level of IGF-1R expression on cell surface. The genetic blockade of IGF-1R by the adenovirus-dnIGF-1R and AG1024 increased the sensitivity of A549 cells to TRAIL. The reduction of IGF-1R by transduction with ad-shIGF-1R also increased the sensitivity of the A549 cells to gefitinib. Conclusion: The blockade of IGF-1R through various mechanisms increased the sensitivity of the lung cancer cell line that was resistant to TRAIL and gefitinib. However, further studies using other cell lines showing acquired resistance as well as in vivo animal experiments will be needed.

Original languageEnglish
Pages (from-to)42-51
Number of pages10
JournalTuberculosis and Respiratory Diseases
Volume63
Issue number1
DOIs
Publication statusPublished - 2007 Jan 1

Fingerprint

Lung Neoplasms
Adenoviridae
Cell Line
Protein-Tyrosine Kinases
Drug Resistance
Small Interfering RNA
gefitinib
Apoptosis
Cytokines
Pharmaceutical Preparations
Neoplasms
A549 Cells
tyrphostin AG 1024

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Lee, Yoon Jin ; Park, Mi Young ; kang, youngae ; Kwon, Sung Youn ; Yoon, Ho Il ; Lee, Jae Ho ; Lee, Choon Taek. / Enhancement of sensitivity of human lung cancer cell line to TRAIL and gefitinib by IGF-1R blockade. In: Tuberculosis and Respiratory Diseases. 2007 ; Vol. 63, No. 1. pp. 42-51.
@article{cf36ad5f50084de6be47bdf60624d271,
title = "Enhancement of sensitivity of human lung cancer cell line to TRAIL and gefitinib by IGF-1R blockade",
abstract = "Background: TRAIL is a cytokine that selectively induces apoptosis in various cancer cell lines. Gefitinib is new targeted drug applied in lung cancer that selectively inhibits EGFR tyrosine kinase. However, lung cancers have shown an initial or acquired resistance to these drugs. This study examined the effect of IGF-1R and its blockade on enhancing the sensitivity of lung cancer cell lines to TRAIL and gefitinib. Methods: Two lung cancer cell lines were used in this study. NCI H460 is very sensitive to TRAIL and gefitinib. On the other hand, A549 shows moderate resistance to TRAIL and gefitinib. The IGF-1R blockade was performed using adenoviruses expressing the dominant negative IGF-1R and shRNA to IGF-1R and AG1024 (IGF-1R tyrosine kinase inhibitor). Results: The adenovirus expressing dominant negative IGF-1R(950st) induced the increased expression of defective IGF-1R on the lung cancer cell surface, and the adenovirus-shIGF-1R effectively decreased the level of IGF-1R expression on cell surface. The genetic blockade of IGF-1R by the adenovirus-dnIGF-1R and AG1024 increased the sensitivity of A549 cells to TRAIL. The reduction of IGF-1R by transduction with ad-shIGF-1R also increased the sensitivity of the A549 cells to gefitinib. Conclusion: The blockade of IGF-1R through various mechanisms increased the sensitivity of the lung cancer cell line that was resistant to TRAIL and gefitinib. However, further studies using other cell lines showing acquired resistance as well as in vivo animal experiments will be needed.",
author = "Lee, {Yoon Jin} and Park, {Mi Young} and youngae kang and Kwon, {Sung Youn} and Yoon, {Ho Il} and Lee, {Jae Ho} and Lee, {Choon Taek}",
year = "2007",
month = "1",
day = "1",
doi = "10.4046/trd.2007.63.1.42",
language = "English",
volume = "63",
pages = "42--51",
journal = "Tuberculosis and Respiratory Diseases",
issn = "1738-3536",
publisher = "The Korean Academy of Tuberculosis and Respiratory Diseases",
number = "1",

}

Enhancement of sensitivity of human lung cancer cell line to TRAIL and gefitinib by IGF-1R blockade. / Lee, Yoon Jin; Park, Mi Young; kang, youngae; Kwon, Sung Youn; Yoon, Ho Il; Lee, Jae Ho; Lee, Choon Taek.

In: Tuberculosis and Respiratory Diseases, Vol. 63, No. 1, 01.01.2007, p. 42-51.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enhancement of sensitivity of human lung cancer cell line to TRAIL and gefitinib by IGF-1R blockade

AU - Lee, Yoon Jin

AU - Park, Mi Young

AU - kang, youngae

AU - Kwon, Sung Youn

AU - Yoon, Ho Il

AU - Lee, Jae Ho

AU - Lee, Choon Taek

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Background: TRAIL is a cytokine that selectively induces apoptosis in various cancer cell lines. Gefitinib is new targeted drug applied in lung cancer that selectively inhibits EGFR tyrosine kinase. However, lung cancers have shown an initial or acquired resistance to these drugs. This study examined the effect of IGF-1R and its blockade on enhancing the sensitivity of lung cancer cell lines to TRAIL and gefitinib. Methods: Two lung cancer cell lines were used in this study. NCI H460 is very sensitive to TRAIL and gefitinib. On the other hand, A549 shows moderate resistance to TRAIL and gefitinib. The IGF-1R blockade was performed using adenoviruses expressing the dominant negative IGF-1R and shRNA to IGF-1R and AG1024 (IGF-1R tyrosine kinase inhibitor). Results: The adenovirus expressing dominant negative IGF-1R(950st) induced the increased expression of defective IGF-1R on the lung cancer cell surface, and the adenovirus-shIGF-1R effectively decreased the level of IGF-1R expression on cell surface. The genetic blockade of IGF-1R by the adenovirus-dnIGF-1R and AG1024 increased the sensitivity of A549 cells to TRAIL. The reduction of IGF-1R by transduction with ad-shIGF-1R also increased the sensitivity of the A549 cells to gefitinib. Conclusion: The blockade of IGF-1R through various mechanisms increased the sensitivity of the lung cancer cell line that was resistant to TRAIL and gefitinib. However, further studies using other cell lines showing acquired resistance as well as in vivo animal experiments will be needed.

AB - Background: TRAIL is a cytokine that selectively induces apoptosis in various cancer cell lines. Gefitinib is new targeted drug applied in lung cancer that selectively inhibits EGFR tyrosine kinase. However, lung cancers have shown an initial or acquired resistance to these drugs. This study examined the effect of IGF-1R and its blockade on enhancing the sensitivity of lung cancer cell lines to TRAIL and gefitinib. Methods: Two lung cancer cell lines were used in this study. NCI H460 is very sensitive to TRAIL and gefitinib. On the other hand, A549 shows moderate resistance to TRAIL and gefitinib. The IGF-1R blockade was performed using adenoviruses expressing the dominant negative IGF-1R and shRNA to IGF-1R and AG1024 (IGF-1R tyrosine kinase inhibitor). Results: The adenovirus expressing dominant negative IGF-1R(950st) induced the increased expression of defective IGF-1R on the lung cancer cell surface, and the adenovirus-shIGF-1R effectively decreased the level of IGF-1R expression on cell surface. The genetic blockade of IGF-1R by the adenovirus-dnIGF-1R and AG1024 increased the sensitivity of A549 cells to TRAIL. The reduction of IGF-1R by transduction with ad-shIGF-1R also increased the sensitivity of the A549 cells to gefitinib. Conclusion: The blockade of IGF-1R through various mechanisms increased the sensitivity of the lung cancer cell line that was resistant to TRAIL and gefitinib. However, further studies using other cell lines showing acquired resistance as well as in vivo animal experiments will be needed.

UR - http://www.scopus.com/inward/record.url?scp=35948933420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948933420&partnerID=8YFLogxK

U2 - 10.4046/trd.2007.63.1.42

DO - 10.4046/trd.2007.63.1.42

M3 - Article

VL - 63

SP - 42

EP - 51

JO - Tuberculosis and Respiratory Diseases

JF - Tuberculosis and Respiratory Diseases

SN - 1738-3536

IS - 1

ER -